Home The Word Brain	My Amedeo FAQ Privacy About
	Amedeo C49 English + 你好 (nǐ hǎo) = limitless possibilities. Start learning Mandarin Chinese today—for free, forever. Amedeo C49 is completely free, for life. Next week: +49.

Prostate Cancer

Free Subscription 23.06.2025 1 Acta Radiol 1 Cancer 1 Cancer Imaging 1 Cancer Lett 1 Clin Cancer Res 1 Eur J Radiol 1 Eur Radiol 3 Eur Urol 3 Int J Urol 1 J Clin Oncol 2 J Urol 3 Lancet Oncol 1 Mol Ther Oncol 1 Nat Rev Urol 19 Semin Radiat Oncol

Retrieve available abstracts of this week’s articles: HTML format

Single Articles

Acta Radiol

1. CHENG H, Yang B, Cui Y, Liu M, et al
   SyMRI histogram analysis for diagnosing clinically significant prostate cancer.
   Acta Radiol. 2025 Jun 18:2841851251349488. doi: 10.1177/02841851251349488.
   PubMed         Abstract available
   
   

   
   Cancer

2. NIERENGARTEN MB
   Acute toxicity of prostate cancer radiotherapy associated with late toxicity: Acute toxicity following prostate cancer radiotherapy was statistically and significantly associated with late toxicity in patient-reported quality-of-life metrics.
   Cancer. 2025;131:e35886.
   PubMed        
   
   

   
   Cancer Imaging

3. BIAN L, Liu F, Peng Y, Liu X, et al
   Using radiomics model for predicting extraprostatic extension with PSMA PET/CT studies: a comparative study with the Mehralivand grading system.
   Cancer Imaging. 2025;25:77.
   PubMed         Abstract available
   
   

   
   Cancer Lett

4. ZHANG M, Xu Z, Cao Y, Gao C, et al
   Analysis and characterization of extrachromosomal circular DNA in prostate cancer: Potential biomarker discovery from urine, plasma, and tumor samples.
   Cancer Lett. 2025;628:217875.
   PubMed         Abstract available
   
   

   
   Clin Cancer Res

5. HAGE CHEHADE C, Graf RP, Ozay ZI, Gebrael G, et al
   Association of Homologous Recombination Repair Alterations With Outcomes in Patients with Metastatic Hormone-Sensitive Prostate Cancer.
   Clin Cancer Res. 2025 Jun 16. doi: 10.1158/1078-0432.CCR-25-1178.
   PubMed         Abstract available
   
   

   
   Eur J Radiol

6. SINGH D, Chandran A, Panebianco V, Vilaseca J, et al
   MRI capacity assessment for prostate cancer screening in five sites of Europe.
   Eur J Radiol. 2025;190:112235.
   PubMed         Abstract available
   
   

   
   Eur Radiol

7. WOO S, Becker AS, Leithner D, Mayerhoefer ME, et al
   Discordance between prostate MRI and PSMA-PET/CT: the next big challenge for primary prostate tumor assessment?
   Eur Radiol. 2025;35:4043-4054.
   PubMed         Abstract available
   
   

   
   Eur Urol

8. COVAS MOSCHOVAS M, Saikali S, Sandri M, Bravi C, et al
   Outcomes of Salvage Robotic-assisted Radical Prostatectomy: High-volume Multicentric Data from the European Association of Urology Robotic Urology Section Scientific Working Group.
   Eur Urol. 2025;88:103-113.
   PubMed         Abstract available
   
   
9. COOPERBERG MR, Grummet J, Eggener SE
   Re: Rajal B. Shah, Gladell P. Paner, Liang Cheng, et al. Genitourinary Pathology Society and International Society of Urological Pathology White Paper on Defining Indolent Prostate Cancer: Call for a Multidisciplinary Approach. Eur Urol. In press. htt
   Eur Urol. 2025 Jun 12:S0302-2838(25)00331-8. doi: 10.1016/j.eururo.2025.
   PubMed        
   
   
10. SCHOOTS IG, Ahmed HU, Albers P, Asbach P, et al
    Magnetic Resonance Imaging-based Biopsy Strategies in Prostate Cancer Screening: A Systematic Review.
    Eur Urol. 2025 Jun 12:S0302-2838(25)00341-0. doi: 10.1016/j.eururo.2025.
    PubMed         Abstract available
    
    

    
    Int J Urol

11. TASHIRO K, Mori K, Shiota M, Fukuokaya W, et al
    Risk Model for Lymph Node-Positive Prostate Cancer After Radical Prostatectomy.
    Int J Urol. 2025 Jun 16. doi: 10.1111/iju.70149.
    PubMed         Abstract available
    
    
12. YASUDA Y, Numao N, Matsumoto S, Tamiya T, et al
    Preliminary Report on the Efficacy and Safety of Triplet Therapy in Patients With Metastatic Hormone-Sensitive Prostate Cancer: YUSHIMA Study.
    Int J Urol. 2025 Jun 16. doi: 10.1111/iju.70154.
    PubMed         Abstract available
    
    
13. WATANABE R
    Editorial Comment to "VIRMA Accelerates the Tumorigenesis of Prostate Cancer via Regulating the m6A Modification of NSMCE2 to Eliminate the Generation of Reactive Oxygen Species".
    Int J Urol. 2025 Jun 16. doi: 10.1111/iju.70150.
    PubMed        
    
    

    
    J Clin Oncol

14. WANG JH, Sherry AD, Bazyar S, Sutera P, et al
    Outcomes of Radium-223 and Stereotactic Ablative Radiotherapy Versus Stereotactic Ablative Radiotherapy for Oligometastatic Prostate Cancers: The RAVENS Phase II Randomized Trial.
    J Clin Oncol. 2025;43:2059-2068.
    PubMed         Abstract available
    
    

    
    J Urol

15. DOMINGO MR, Seibert TM
    Reply: Restriction Spectrum Imaging as a Quantitative Biomarker for Prostate Cancer With Reliable Positive Predictive Value.
    J Urol. 2025 Jun 20:101097JU0000000000004634. doi: 10.1097/JU.0000000000004634.
    PubMed        
    
    
16. FOGG RW, Krzastek SC, Vissichelli N, Defor E, et al
    Defining Abnormal Prostate Specific Antigen Values for Prostate Cancer Screening in the Spinal Cord Injury Population.
    J Urol. 2025 Jun 17:101097JU0000000000004644. doi: 10.1097/JU.0000000000004644.
    PubMed         Abstract available
    
    

    
    Lancet Oncol

17. TREE AC, Hinder V, Chan A, Tolan S, et al
    Intensity-modulated moderately hypofractionated radiotherapy versus stereotactic body radiotherapy for prostate cancer (PACE-C): early toxicity results from a randomised, open-label, phase 3, non-inferiority trial.
    Lancet Oncol. 2025 Jun 12:S1470-2045(25)00205.
    PubMed         Abstract available
    
    
18. MUKHERJI D, Omlin A
    CONTACT-02 and beyond: rethinking immunotherapy strategies in metastatic prostate cancer.
    Lancet Oncol. 2025 Jun 13:S1470-2045(25)00266.
    PubMed        
    
    
19. AGARWAL N, Azad AA, Carles J, Matsubara N, et al
    Cabozantinib plus atezolizumab in metastatic prostate cancer (CONTACT-02): final analyses from a phase 3, open-label, randomised trial.
    Lancet Oncol. 2025 Jun 13:S1470-2045(25)00209.
    PubMed         Abstract available
    
    

    
    Mol Ther Oncol

20. VAZQUEZ-ARREGUIN K
    Novel synthetic peptide-based vaccine shows promise against prostate cancer.
    Mol Ther Oncol. 2025;33:201000.
    PubMed        
    
    

    
    Nat Rev Urol

21. MASONE MC
    Acupuncture to reduce nocturia in survivors of prostate cancer.
    Nat Rev Urol. 2025 Jun 16. doi: 10.1038/s41585-025-01059.
    PubMed        
    
    

    
    Semin Radiat Oncol

22. PATEL KR, Abel M, Basourakos SP, Citrin DE, et al
    Optimizing Radiation Therapy for Localized Prostate Cancer: Exploring Synergies With Androgen Deprivation Therapy and Novel Systemic Agents.
    Semin Radiat Oncol. 2025;35:474-487.
    PubMed         Abstract available
    
    
23. CIVAN C, Guberina N, Krafft U, Fendler WP, et al
    Radiopharmaceuticals in Prostate Cancer: General Considerations and Utility in Combination With EBRT.
    Semin Radiat Oncol. 2025;35:463-473.
    PubMed         Abstract available
    
    
24. KAMRAN SC, Gao X, Zamboglou C
    Radiotherapy for High-Risk Prostate Cancer.
    Semin Radiat Oncol. 2025;35:301-303.
    PubMed        
    
    
25. GARDNER U, Randolph AB, Anabaraonye N, Washington C, et al
    Health Disparities and Inequities in Prostate Cancer Along the Continuum of Care.
    Semin Radiat Oncol. 2025;35:304-316.
    PubMed         Abstract available
    
    
26. DRAGONETTI V, Colandrea M, Travaini L, Airo Farulla LS, et al
    PSMA-PET Guided Radiotherapy in Prostate Cancer: A Critical Review of Current Applications and Future Directions.
    Semin Radiat Oncol. 2025;35:317-324.
    PubMed         Abstract available
    
    
27. YANG DD, Nguyen PL
    Novel biomarkers for guiding treatment for prostate cancer.
    Semin Radiat Oncol. 2025;35:325-332.
    PubMed         Abstract available
    
    
28. CHAKRABARTI D, Green H, Tree A
    Hypofractionation/Ultra-hypofractionation for Prostate Cancer Radiotherapy.
    Semin Radiat Oncol. 2025;35:333-341.
    PubMed         Abstract available
    
    
29. CASILLAS JEJ, Valle LF, Pham J, O'Connell D, et al
    Advancing Prostate Cancer Treatment: A Review of CT and MR-Guided Online Adaptive Radiotherapy Techniques.
    Semin Radiat Oncol. 2025;35:342-352.
    PubMed         Abstract available
    
    
30. PEPIN A, Goel A, Vapiwala N
    The Use of Particle Therapy in Prostate Cancer.
    Semin Radiat Oncol. 2025;35:353-361.
    PubMed         Abstract available
    
    
31. MELTON M, Angrisani A, Simpson A, McDonald A, et al
    Radiation Therapy in Node-Positive Prostate Cancer: Current Evidence and Future Directions.
    Semin Radiat Oncol. 2025;35:362-373.
    PubMed         Abstract available
    
    
32. CHILUKURI S, Sayan M, Pra AD, Murthy V, et al
    Elective Regional Nodal Irradiation in Prostate Cancer.
    Semin Radiat Oncol. 2025;35:374-384.
    PubMed         Abstract available
    
    
33. SUNDARESAN VM, Leapman MS
    Debate 1: Radical Prostatectomy For the Right Patient With High-Risk Prostate Cancer.
    Semin Radiat Oncol. 2025;35:385-392.
    PubMed         Abstract available
    
    
34. ROONEY MK, El Kouzi Z, Kouzy R, Mohamad O, et al
    Debate 1: High-Risk Localized Prostate Cancer: Why Combination Hormone Therapy and Radiotherapy is the Optimal Treatment Strategy for Most Men.
    Semin Radiat Oncol. 2025;35:393-401.
    PubMed         Abstract available
    
    
35. CHOWDHURY AA, Hoskin PJ
    Debate 2: Primary Localized Prostate Cancer: The Case for Whole-Gland Brachytherapy Boost.
    Semin Radiat Oncol. 2025;35:402-414.
    PubMed         Abstract available
    
    
36. DORNISCH AM, Seibert TM
    Debate 2: The Case for Focal External Beam Radiation Therapy Boost Over Brachytherapy Boost for Prostate Cancer.
    Semin Radiat Oncol. 2025;35:415-422.
    PubMed         Abstract available
    
    
37. SINGH M, Murthy V, Ost P
    Debate 3: Metastasis Directed Therapy in Oligometastatic Prostate Cancer.
    Semin Radiat Oncol. 2025;35:423-432.
    PubMed         Abstract available
    
    
38. VON AMSBERG G, Kaune M, Coym A, Strewinsky N, et al
    Debate 3: Oligometastatic Hormone Sensitive Prostate Cancer Management: Systemic Therapy Approach.
    Semin Radiat Oncol. 2025;35:433-438.
    PubMed         Abstract available
    
    
39. ACHARD V, Pra AD, Sargos P
    Postoperative Radiation Therapy and Controversies Regarding Hormonal Therapy in the Management of Prostate Cancer.
    Semin Radiat Oncol. 2025;35:439-449.
    PubMed         Abstract available
    
    
40. POZIN J, Bhandari M, Valle L, Nickols NG, et al
    The Evolving Management of Radiorecurrent Prostate Cancer.
    Semin Radiat Oncol. 2025;35:450-462.
    PubMed         Abstract available
    
    

Thank you for your interest in scientific medicine.

AMEDEO Prostate Cancer is free of charge.